Skip to content

Bausch Health

US · BHC #2722 by market cap Listed 1970
8.22 -0.34 -3.97%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:46

Valuation each multiple against its own 5-year range

P/B ratio -2.35 Expensive vs history 70th percentile
5-year average -8.81
P/E ratio -3.71 In line with history 57th percentile
5-year average -3.99 · forward 5.01
P/S ratio 0.28 In line with history 43rd percentile
5-year average 0.36 · forward 0.29 · #7 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Bausch Health (BHC) 3.08B -3.65 -2.32 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value9.96 Economic moatNone UncertaintyHigh

Trading 21.1% below Morningstar's fair value estimate.

Fair value

Bausch Health Companies Inc receives a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 16% discount to our quantitative fair value estimate of $9.96 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's profitability strengthens our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's earnings yield of 60.5% ranks in the top 10% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are undervalued.

The firm's balance sheet is an additional encouraging factor. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. The firm's EBITDA/interest coverage ratio of 1.5, for example, lies in the bottom 20% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. This characteristic further promotes our favorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the company's weak financial health rating could portend bankruptcy risk if economic conditions weaken.

By Quantitative Equity Report

Quote time 2026-11-20 19:46:13 · For reference only, not investment advice and not tailored to your situation.

Bausch Health discussion 0 comments

Add a comment